Iterum Historical Income Statement
| ITRM Stock | USD 1.99 0.18 9.94% |
Historical analysis of Iterum Therapeutics income statement accounts such as Depreciation And Amortization of 1.8 M or Interest Expense of 1.4 M can show how well Iterum Therapeutics PLC performed in making a profits. Evaluating Iterum Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Iterum Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Iterum Therapeutics PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iterum Therapeutics PLC is a good buy for the upcoming year.
Iterum |
About Iterum Income Statement Analysis
Iterum Therapeutics PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Iterum Therapeutics shareholders. The income statement also shows Iterum investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Iterum Therapeutics Income Statement Chart
Add Fundamental
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Iterum Therapeutics PLC. It is also known as Iterum Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Iterum Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Iterum Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Iterum Therapeutics' Interest Income is very stable compared to the past year. As of the 25th of November 2024, Depreciation And Amortization is likely to grow to about 1.8 M, while Net Interest Income is likely to drop (990.1 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 2.1M | 1.8M | 1.7M | 969.1K | Income Tax Expense | 705K | 301K | 613K | 527.3K |
Iterum Therapeutics income statement Correlations
Click cells to compare fundamentals
Iterum Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Iterum Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (861K) | (17.9M) | (5.6M) | (2.4M) | (943K) | (990.2K) | |
| Depreciation And Amortization | 196K | 161K | 2.1M | 1.8M | 1.8M | 1.8M | |
| Interest Expense | 861K | 15.1M | 5.6M | 2.4M | 1.4M | 1.4M | |
| Selling General Administrative | 11.3M | 11.1M | 13.8M | 12.8M | 7.5M | 10.0M | |
| Gross Profit | 37K | (161K) | (2.1M) | (1.8M) | (1.8M) | (1.7M) | |
| Other Operating Expenses | 102.1M | 32.1M | 24.5M | 30.4M | 47.5M | 49.1M | |
| Operating Income | (102.0M) | (32.1M) | (24.5M) | (30.4M) | (47.5M) | (49.8M) | |
| Net Income From Continuing Ops | (103.1M) | (52.0M) | (91.6M) | (44.4M) | (31.1M) | (32.7M) | |
| Ebit | (102.0M) | (36.2M) | (85.3M) | (41.8M) | (36.3M) | (38.1M) | |
| Research Development | 90.8M | 21.1M | 10.7M | 17.6M | 40.0M | 28.4M | |
| Ebitda | (101.8M) | (36.0M) | (83.2M) | (40.0M) | (34.6M) | (36.3M) | |
| Total Operating Expenses | 102.1M | 32.1M | 24.5M | 30.4M | 47.5M | 49.1M | |
| Income Before Tax | (102.7M) | (51.3M) | (90.9M) | (44.1M) | (37.8M) | (39.6M) | |
| Total Other Income Expense Net | (665K) | (19.1M) | (66.3M) | (13.8M) | 9.7M | 10.2M | |
| Net Income Applicable To Common Shares | (103.1M) | (52.0M) | (91.6M) | (44.4M) | (40.0M) | (42.0M) | |
| Net Income | (103.1M) | (52.0M) | (91.6M) | (44.4M) | (38.4M) | (40.3M) | |
| Reconciled Depreciation | 152K | 161K | 2.1M | 1.8M | 1.7M | 969.1K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.